Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:ICCM NASDAQ:ITOC NASDAQ:OSRH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.43-4.3%$0.47$0.31▼$1.14$27.12M-2.26412,557 shs524,290 shsICCMIceCure Medical$0.24-4.0%$0.45$0.24▼$1.40$20.30M0.47525,995 shs514,020 shsITOCItonic$0.32-7.1%$0.33$0.25▼$32.00$5.80M3.232.55 million shs235,970 shsOSRHOSR$0.57-17.5%$0.52$0.38▼$1.79$22.89M0.8617.52 million shs2.73 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys0.00%+22.97%+12.84%-11.59%-60.36%ICCMIceCure Medical0.00%-12.59%-25.95%-57.63%-76.30%ITOCItonic0.00%-6.28%+9.32%+33,999,900.00%+33,999,900.00%OSRHOSR0.00%-1.68%+40.47%+25.65%-45.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.43-4.3%$0.47$0.31▼$1.14$27.12M-2.26412,557 shs524,290 shsICCMIceCure Medical$0.24-4.0%$0.45$0.24▼$1.40$20.30M0.47525,995 shs514,020 shsITOCItonic$0.32-7.1%$0.33$0.25▼$32.00$5.80M3.232.55 million shs235,970 shsOSRHOSR$0.57-17.5%$0.52$0.38▼$1.79$22.89M0.8617.52 million shs2.73 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys0.00%+22.97%+12.84%-11.59%-60.36%ICCMIceCure Medical0.00%-12.59%-25.95%-57.63%-76.30%ITOCItonic0.00%-6.28%+9.32%+33,999,900.00%+33,999,900.00%OSRHOSR0.00%-1.68%+40.47%+25.65%-45.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 2.60Moderate Buy$5.501,179.37% UpsideICCMIceCure Medical 2.25Hold$2.64997.92% UpsideITOCItonic 1.00SellN/AN/AOSRHOSR 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ITOC, OSRH, ICCM, and FEMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026ICCMIceCure Medical Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/1/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026ICCMIceCure Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026OSRHOSR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/3/2026FEMYFemasys Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$1.502/10/2026ITOCItonic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$2.29M11.34N/AN/A$0.10 per share4.30ICCMIceCure Medical$3.38M5.76N/AN/A$0.12 per share2.00ITOCItonic$520K10.36N/AN/A$0.48 per share0.66OSRHOSR$2.91M6.49N/AN/A$4.95 per share0.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.63M-$0.50N/AN/AN/A-812.74%-534.94%-116.29%N/AICCMIceCure Medical-$15.06M-$0.24N/AN/AN/A-445.61%-221.04%-118.89%5/14/2026 (Estimated)ITOCItonic-$5.10MN/AN/AN/AN/AN/AN/AN/AN/AOSRHOSR-$27.06M-$1.28N/AN/AN/A-619.82%-13.53%-10.17%N/ALatest ITOC, OSRH, ICCM, and FEMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ICCMIceCure Medical-$0.03N/AN/AN/A$1.34 millionN/A5/8/2026Q1 2026FEMYFemasys-$0.0667$0.0049+$0.0716N/A$0.77 million$0.42 million3/31/2026Q4 2025FEMYFemasys-$0.0833-$0.01+$0.0733-$0.01$1.06 million$0.81 million3/30/2026Q4 2025ITOCItonicN/A-$0.0910N/A-$0.0910N/A$0.23 million3/17/2026Q4 2025ICCMIceCure Medical-$0.04-$0.06-$0.02-$0.0620$1.30 million$1.28 million2/15/2026Q4 2025ICCMIceCure MedicalN/A$0.06N/A$0.06N/A$1.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/AITOCItonicN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.894.532.95ICCMIceCure MedicalN/A2.612.07ITOCItonicN/A8.838.72OSRHOSRN/A0.160.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%ICCMIceCure Medical0.62%ITOCItonicN/AOSRHOSR55.30%Insider OwnershipCompanyInsider OwnershipFEMYFemasys7.55%ICCMIceCure Medical2.44%ITOCItonicN/AOSRHOSR60.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3060.39 million55.83 millionNot OptionableICCMIceCure Medical6081.18 million79.20 millionNot OptionableITOCItonicN/A17.05 millionN/AN/AOSRHOSRN/A33.12 million13.05 millionN/AITOC, OSRH, ICCM, and FEMY HeadlinesRecent News About These CompaniesEmerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price TargetMay 5, 2026 | accessnewswire.comAOSR Holdings, Inc. Common Stock (OSRH) SEC FilingsMay 2, 2026 | nasdaq.comOSRH stock rockets 60% on $815M immunotherapy deal — retail bulls eye $1 mark for the stockApril 30, 2026 | msn.comOSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026April 30, 2026 | accessnewswire.comAOSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM EuropeApril 29, 2026 | accessnewswire.comAOSR Holdings Appoints New COO to Bolster Healthcare FocusApril 22, 2026 | tipranks.comOSR Holdings, Inc.: OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible NoteApril 10, 2026 | finanznachrichten.deOSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible NoteApril 9, 2026 | accessnewswire.comAOSR Holdings Revises Global License Deal for VXM01April 2, 2026 | tipranks.comOSR Holdings, Inc.: OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026March 31, 2026 | finanznachrichten.deOSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026March 30, 2026 | wfxg.comWEmerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price TargetMarch 27, 2026 | accessnewswire.comAOSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent LevelMarch 23, 2026 | accessnewswire.comAOSR Holdings, Inc.: Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial OpportunitiesMarch 19, 2026 | finanznachrichten.deWoori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter TrialsMarch 19, 2026 | taiwannews.com.twTWoori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial OpportunitiesMarch 19, 2026 | accessnewswire.comAOSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic MomentumMarch 5, 2026 | accessnewswire.comAOSR Holdings, Inc. Common Stock (OSRH) Institutional HoldingsFebruary 3, 2026 | nasdaq.comOSR Holdings, Inc.: CEO Statement to ShareholdersFebruary 2, 2026 | finanznachrichten.deCEO Statement to ShareholdersFebruary 2, 2026 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeITOC, OSRH, ICCM, and FEMY Company DescriptionsFemasys NASDAQ:FEMY$0.43 -0.02 (-4.28%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.45 +0.02 (+5.14%) As of 05/8/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.IceCure Medical NASDAQ:ICCM$0.24 -0.01 (-4.00%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.24 +0.00 (+1.25%) As of 05/8/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Itonic NASDAQ:ITOC$0.32 -0.02 (-7.06%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.31 0.00 (-0.95%) As of 05/8/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients. The company was formerly known as Pheton Holdings Ltd and changed its name to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. was founded in 1998 and is headquartered in Beijing, China. iTonic Holdings Ltd. operates as a subsidiary of ZJW (BVI) LTD.OSR NASDAQ:OSRH$0.57 -0.12 (-17.45%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.58 +0.01 (+1.84%) As of 05/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
